1. The Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Diabetes Care 1999;22(suppl 1):5.
2. World Health Organization Study Group. Diabetes mellitus. Technical reports series no. 727. Geneva: World Health Organization, 1985:9.
3. Taylor SI. Lilly Lecture. Molecular mechanisms of insulin resistance: lessons from patients with mutations in the insulin-receptor gene. Diabetes 1992;41:1473.
4. Froguelle P, Zouali H, Bionnet N, et al. Familial hyperglycemia due to mutations in glucokinase: definition of a new subtype of non–insulin-dependent (type 2) diabetes mellitus. N Engl J Med 1993; 328:697.
5. Yamagata K, Oda N, Kaisaki PJ, et al. Mutations in the hepatocyte nuclear factor-1-alpha gene in maturity onset diabetes of the young (MODY3). Nature 1996;384:455.
6. Yamagata K, Furata H, Oda N, et al. Mutations in the hepatocyte nuclear factor-4-alpha gene in maturity onset diabetes of the young (MODY1). Nature 1996;384:458.
7. Stoffers DA, Ferrer J, Clarke WL, et al. Early-onset type-II diabetes mellitus (MODY4) linked to IPF1. Nat Genet 1997;17:138.
8. Horikawa Y, Iwasaki N, Hara M, et al. Mutation in hepatocyte nuclear factor-1b gene (TCF2) associated with MODY. Nat Genet 1997;17:384–385.
9. West KM. Epidemiology of diabetes and its vascular lesions. New York: Elsevier, 1978.
10. West KM, Kalbfleisch JM. Influence of nutritional factors on prevalence of diabetes. Diabetes 1971;20:99.
11. Joslin EP. The prevention of diabetes mellitus. JAMA 1921;76:79.
12. Arner P, Pollare T, Lithell H. Different aetiologies of type 2 (non-insulin-dependent) diabetes mellitus in obese and non-obese subjects. Diabetologia 1991;34:483.
13. Mohan, V, Vijayaprabha R, Rema M, et al. Clinical profile of lean NIDDM in South India. Diabetes Res Clin Pract 1997;38:101.
14. Banerji MA, Faridi N, Atluri R, et al. Body composition, visceral fat, leptin, and insulin resistance in Asian Indian men. J Clin Endocrinol Metab 1999;84:137.
15. Vague J. The degree of masculine differentiation of obesities: a factor determining predisposition to diabetes, atherosclerosis, gout, and uric calculus disease. Am J Clin Nutr 1956;4:20.
16. Feldman R, Sender AJ, Siegelaub AB. Difference in diabetic and nondiabetic fat distribution patterns by skinfold measurements. Diabetes 1969;18:478.
17. Hartz AJ, Rupley DC, Rimm AA. The association of girth measurements with disease in 32,856 women. Am J Epidemiol 1984;119:71.
18. Yalow RS, Berson SA. Immunoassay of endogenous plasma insulin in man. J Clin Invest 1960;39:1157.
19. Reaven G, Miller R. Study of the relationship between glucose and insulin responses to an oral glucose load in man. Diabetes 1968;17: 560.
20. Welborn TA, Stenhouse NS, Johnstone CG. Factors determining serum-insulin response in a population sample. Diabetologia 1969; 5:263.
21. DeFronzo RA. Lilly Lecture 1987. The triumvirate: β-cell, muscle, liver: a collusion responsible for type 2 diabetes. Diabetes 1988;37:667.
22. DeFronzo RA, Ferrannini E. The pathogenesis of non–insulin-dependent diabetes: an update. Medicine (Baltimore) 1982;62:125.
23. Porte D Jr. Banting Lecture 1990. β-cells in type II diabetes mellitus. Diabetes 1991;40:166.
24. Halter JB, Graf RJ, Porte D Jr. Potentiation of insulin secretory responses by plasma glucose levels in man: evidence that hyperglycemia in diabetes compensates for impaired glucose potentiation. J Clin Endocrinol Metab 1979;48:946.
25. Yoneda H, Ikagami H, Yamamoto Y, et al. Analysis of early phase insulin responses in non-obese subjects with mild glucose intolerance. Diabetes Care 1992;15:1517.
26. Himsworth HP, Kerr RB. Insulin-sensitive and insulin-insensitive types of diabetes mellitus. Clin Sci 1942;4:120.
27. Yalow RS, Berson SA. Plasma insulin concentrations in nondiabetics and early diabetic subjects. Diabetes 1960;9:254.
28. Butterfield WJH, Whichelow MJ. Peripheral glucose metabolism in control subjects and diabetic patients during glucose, glucose-insulin and insulin sensitivity tests. Diabetologia 1965;1:43.
29. Jackson RA, Perry G, Rogers J, et al. Relationship between the basal glucose concentrations, glucose tolerance and forearm glucose uptake in maturity-onset diabetes. Diabetes 1973;22:751.
30. Zierler KI, Rabinowitz D. Roles of insulin and growth hormone, based on studies of forearm metabolism in man. Medicine (Baltimore) 1963;42:385.
31. Alford FP, Martin FIP, Pearson MJ. The significance of interpretation of mildly abnormal oral glucose tolerance. Diabetologia 1971;7:173.
32. Reaven GM, Farquhar JW. Steady state plasma insulin response to continuous glucose infusion in normal and diabetic subjects. Diabetes 1969;18:273.
33. Harano Y, Ohgaku S, Hidaka H, et al. Glucose insulin and somatostatin infusion for the determination of insulin sensitivity. J Clin Endocrinol Metab 1977;45:1124.
34. DeFronzo RA, Tobin JD, Andres R. Glucose clamp technique: a method for quantifying insulin secretion and resistance. Am J Physiol 1979;6:E214.
35. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988;37:1595.
36. Kolterman OG, Gray RS, Griffin J, et al. Receptor and post-receptor defects contribute to the insulin resistance in non-insulin dependent diabetes mellitus. J Clin Invest 1981;68:957.
37. Bogardus C, Lillioja S, Howard B, et al. Relationships between insulin secretion, insulin action and fasting plasma glucose concentration in non-diabetic and non–insulin-dependent diabetic subjects. J Clin Invest 1984;74:1238.
38. Rizza RA, Mandarino LJ, Gerich JE. Mechanism and significance of insulin resistance in non–insulin-dependent diabetes mellitus. Diabetes 1981;30:990.
39. Bergman RN, Phillips LS, Cobelli C. Physiologic evaluation of factors controlling glucose tolerance in man: measurement of insulin sensitivity and beta-cell glucose sensitivity from the response to intravenous glucose. J Clin Invest 1981;68:1456.
40. Bergman RN. Lilly Lecture 1989. Toward physiological understanding of glucose tolerance: minimal-model approach. Diabetes 1989; 38:1512.
41. Saad MF, Anderson RL, Laws A, et al. A comparison between the minimal model and the glucose clamp in the assessment of insulin sensitivity across the spectrum of glucose tolerance: Insulin Resistance Atherosclerosis Study. Diabetes 1994;43:1114.
42. Haffner SM, Howard G, Mayer E, et al. Insulin sensitivity and acute insulin response in African-Americans, non-Hispanic whites, and Hispanics with NIDDM: the Insulin Resistance Atherosclerosis Study. Diabetes 1997;46:63.
43. Caro JF, Dohm LG, Pories WJ, et al. Cellular alterations in liver, skeletal muscle, and adipose tissue responsible for insulin resistance in obesity and type II diabetes mellitus. Diabetes Metab Rev 1989;5: 665.
44. Olefsky JM, Garvey WT, Henry RR, et al. Cellular mechanisms of insulin resistance in non–insulin-dependent (type II) diabetes. Am J Med 1988;85(suppl 5A):86.
45. Arner P, Pollare T, Lithell H, et al. Defective insulin receptor tyrosine kinase in human skeletal muscle in obesity and type 2 (non–insulin-dependent) diabetes mellitus. Diabetologia 1987;30:437.
46. Obermaier-Kusser B, White MF, Pongratz DE, et al. A defective intramolecular autoactivation cascade may cause the reduced kinase activity of the skeletal muscle insulin receptor from patients with non-insulin dependent diabetes mellitus. J Biol Chem 1989;264:9497.
47. Thorburn AW, Gumbiner B, Bulacan F, et al. Multiple defects in glycogen synthase activity contribute to reduced glycogen synthesis in non-insulin dependent diabetes mellitus. J Clin Invest 1991;87:489.
48. Damsbo P, Vaag A, Hother-Nielson O, et al. Reduced glycogen synthase activity in skeletal muscle from obese patients with and without type 2 (non–insulin-dependent) diabetes mellitus. Diabetologia 1991;34:239.
49. Wright KS, Beck-Nielsen H, Kolterman O, et al. Decreased activation of skeletal muscle glycogen synthase by mixed-meal ingestion in type 2 diabetes. Diabetes 1988;37:436.
50. Hansen T, Andersen CB, Echwald SM, et al. Identification of a common amino acid polymorphism in the p85alpha regulatory subunit of phosphatidylinositol 3-kinase: effects on glucose disappearance constant, glucose effectiveness, and the insulin sensitivity index. Diabetes 1997;46:494.
51. Foley JE. Mechanism of impaired insulin action in isolated adipocytes from obese and diabetic subjects. Diabetes Metab Rev 1988;4:487.
52. Bogardus C, Lillioja S, Stone K, et al. Correlation between muscle glycogen synthase activity and in vivo insulin action in man. J Clin Invest 1984;73:1185.
53. Kida YA, Esposito-Del Puente A, Bogardus C, et al. Insulin resistance is associated with reduced fasting and insulin-stimulated glycogen synthase phosphatase activity in human skeletal muscle. J Clin Invest 1990;85:476.
54. Nyomba BL, Ossowski VM, Bogardus C, et al. Insulin-sensitive tyrosine kinase: relationship with in vivo insulin action in human. Am J Physiol 1990;250:E964.
55. Kida Y, Nyomba BL, Bogardus C, Mott DM. Defective insulin response of cyclic adenosine monophosphate dependent protein kinase in insulin-resistant human. J Clin Invest 1991;87:673.
56. Sommercorn J, Fields R, Raz I, et al. Abnormal regulation of ribosomal protein S6 kinase in insulin skeletal muscle of insulin-resistant humans. J Clin Invest 1993;91:509.
57. McGuire MC, Fields RM, Nyomba BL, et al. Abnormal regulation of protein tyrosine phosphatase activities in skeletal muscle of insulin-resistant humans. Diabetes 1991;40:939.
58. Pessin JE, Saltiel AR. Signaling pathways in insulin action: molecular targets of insulin resistance. J Clin Invest 2000;106:165–169.
59. Kido Y, Nakae J, Accili D. Clinical review 125: the insulin receptor and its cellular targets. J Clin Endocrinol Metab 2001;86:972–979.
60. DeFronzo RA, Gunnarsson R, Bjorkman O, et al. Effects of insulin on peripheral and splanchnic glucose metabolism in noninsulin dependent (type II) diabetes mellitus. J Clin Invest 1985;76:149.
61. Kelly DE, Mokaw M, Mandarino LJ. Intracellular defects in glucose metabolism in obese patients with type 2 diabetes. Diabetes 1992;41: 698.
62. Shulman GI, Rothman DL, Jue T, et al. Quantitation of muscle glycogen synthesis in normal subjects and subjects with non–insulin-dependent diabetes by 13C nuclear magnetic resonance spectroscopy. N Engl J Med 1989;322:223.
63. Ferrannini E, Groop LC. Hepatic glucose production in insulin-resistant states. Diabetes Metab Rev 1989;5711.
64. Elbein SC, Ward WK, Bearch JC, et al. Familial type 2 diabetes: molecular-genetic analysis and assessment of insulin action and pancreatic β-cell function. Diabetes 1988;37:377.
65. Lillioja S, Bogardus C. Obesity and insulin resistance: lessons learned from the Pima Indians. Diabetes Metab Rev 1988;4:517.
66. Lillioja S, Mott DM, Zawadzki JK, et al. In vivo insulin action is a familial characteristic in non-diabetic Pima Indians. Diabetes 1987; 36:1329.
67. Mittelman SD, Fu YY, Rebrin K, et al. Indirect effect of insulin to suppress endogenous glucose production is dominant, even with hyperglucagonemia. J Clin Invest 1997;100:3121.
68. Westlund K, Nicolaysen R. Ten year mortality and morbidity related to serum cholesterol: a follow-up of 3,751 men aged 40–49. Scand J Lab Clin Invest 1972;30(suppl 127):1.
69. Ohlson L-O, Larsson B, Eriksson H, et al. Diabetes in Swedish middle-aged men: the study of men born in 1913 and 1923. Diabetologia 1987;30:386.
70. Madelie JH, Herman JB, Goldbourt U, et al. Variations in incidence of diabetes among 10,000 adult Israeli males and the factors related to their development. In: Levine R, Luft R, eds. Advances in metabolic disorders. New York: Academic, 1978:93.
71. Modan M, Karasik A, Halkin H, et al. Effect of past and concurrent body mass index on prevalence of glucose intolerance and type 2 (non–insulin-dependent) diabetes and on insulin response: the Israeli Study of Glucose Intolerance, Obesity and Hypertension. Diabetologia 1986;29:82.
72. O’Sullivan JB, Mahan CM. Blood sugar levels, glycosuria, and body weight related to development of diabetes mellitus. JAMA 1965; 194:587.
73. Dunn JP, Ipsen J, Elsom KO, et al. Risk factors in coronary artery disease, hypertension and diabetes. Am J Med Sci 1970;259:309.
74. Wilson PW, McGee DL, Kannel WB. Obesity, very low density lipoproteins, and glucose intolerance over fourteen years: the Framingham Study. Am J Epidemiol 1981;114:697.
75. Haffner SM, Stern MP, Mitchell BD, et al. Incidence of type II diabetes in Mexican-Americans predicted by fasting insulin and glucose levels, obesity and body fat distribution. Diabetes 1990;39:283.
76. Knowler WC, Pettitt DJ, Saad MF, et al. Diabetes mellitus in the Pima Indians: incidence risk factors and pathogenesis. Diabetes Metab Rev 1990;6:1.
77. Everhart JE, Pettitt DJ, Slaine KR, et al. Duration of obesity is a risk factor for non–insulin-dependent diabetes mellitus. Diabetes 1992; 41:235.
78. Ohlson L-D, Larsson B, Svärdsudd K, et al. The influence of body fat distribution on the incidence of diabetes mellitus: 13.5 years of follow-up of the participants in the study of men born in 1913. Diabetes 1985;34:1055.
79. Lillioja S, Mott DM, Spraul M, et al. Insulin resistance and insulin secretory dysfunction as precursors of non–insulin-dependent diabetes mellitus: prospective studies of Pima Indians. N Engl J Med 1993;329:1988.
80. Bergstrom RW, Newell-Morris LL, Leonetti DL, et al. Association of elevated fasting C-peptide levels and increased abdominal fat distribution with development of type 2 diabetes in Japanese-American men. Diabetes 1990;39:104.
81. Efendic S, Luft R, Wajngot A. Aspects of the pathogenesis of type 2 diabetes. Endocr Rev 1984;5:395.
82. Skarfors ET, Selinus KI, Lithell HO. Risk factors for developing non-insulin dependent diabetes: a 10 year follow up of men in Uppsala. BMJ 1991;303:755.
83. Lundgren H, Bengtsson C, Blohm G, et al. Fasting serum insulin concentration and early insulin response as risk determinants for developing diabetes. Diabetes Med 1990;7:407.
84. Warram JH, Martin BC, Krolewski AS, et al. Slow glucose removal rate and hyperinsulinemia precede the development of type II diabetes in the offspring of diabetic parents. Ann Intern Med 1990;113:909.
85. Martin BC, Warram JH, Krolewski AS, et al. Role of glucose and insulin resistance in development of type 2 diabetes mellitus: results of a 25-year follow-up study. Lancet 1992;340:925.
86. Charles MA, Fontbonne A, Thibult N, et al. Risk factors for type 2 diabetes in white population: Paris prospective study. Diabetes 1991; 40:796.
87. Sicree RA, Zimmet PZ, King HOM, et al. Plasma insulin response among Nauruans: prediction of deterioration in glucose tolerance over 6 yr. Diabetes 1987;36:179.
88. Kadowaki T, Miyake Y, Hagura R, et al. Risk factors for worsening to diabetes in subjects with impaired glucose tolerance. Diabetologia 1984;26:44.
89. Saad MF, Knowler WC, Pettitt DJ, et al. A two-step model for development of non–insulin-dependent diabetes mellitus. Am J Med 1991;90:229.
90. Weyer C, Bogardus C, Mott DM, et al. The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. J Clin Invest 1999;104:787–794.
91. Taylor SI, Accili D, Imai Y. Perspectives in diabetes: insulin resistance or insulin deficiency: which is the primary cause of type 2 diabetes? Diabetes 1994;43:735.
92. Lillioja S, Nyomba BL, Saad MF, et al. Exaggerated early insulin release and insulin resistance in a diabetes-prone population: a metabolic comparison of Pima Indians and Caucasians. J Clin Endocrinol Metab 1991;73:866.
93. Leahy JL, Cooper HE, Deal DA, et al. Chronic hyperglycemia is associated with impaired glucose influence on insulin secretion: a study in normal rats using chronic in vivo glucose infusions. J Clin Invest 1986;77:908.
94. Unger RH. Lipotoxicity in the pathogenesis of obesity-dependent NIDDM: genetic and clinical implications. Diabetes 1995;44:863.
95. Boden G. Fatty acids and insulin resistance. Diabetes Care 1996; 19:394.
96. Boden G, Chen X. Effects of fatty acids and ketone bodies on basal insulin secretion in type 2 diabetes. Diabetes 1999;48:577.
97. Paolisso G, Gambardella A, Amato L, et al. Opposite effects of short- and long-term fatty acid infusion on insulin secretion in healthy subjects. Diabetologia 1995;38:1296.
98. Pickup JC, Mattock MB, Chusney GD, et al. NIDDM as a disease of the innate immune system: association of acute-phase reactants and interleukin-6 with metabolic syndrome X. Diabetologia 1997; 40:1286–1292.
99. Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia 1998;41:1241–1248.
100. Schmidt MI, Duncan BB, Sharrett AR, et al. Markers of inflammation and prediction of diabetes mellitus in adults (Atherosclerosis Risk in Communities Study): a cohort study. Lancet 1999;353: 1649–1652.
101. Fernandez-Real JM, Ricart W. Insulin resistance and inflammation in an evolutionary perspective: the contribution of cytokine genotype/phenotype to thriftiness. Diabetologia 1999;42:1367–1374.
102. Vozarova B, Weyer C, Lindsay RS, et al. High white blood cell count is associated with a worsening of insulin sensitivity and predicts the development of type 2 diabetes. Diabetes 2002;51:455–461.
103. Weyer C, Yudkin JS, Stehouwer CDA, et al. Humoral markers of inflammation and endothelial dysfunction in relation to adiposity and in vivo insulin action in Pima Indians. Atherosclerosis 2002;161: 233–242.